Yiftach Roth

Dr. Yiftach Roth


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Clinical Neurophysiology
Verified
Journal Article
Closed access
YRYiftach Roth
Yiftach Roth
GPGaby S. Pell
Gaby S. Pell
ACAndrei V. Chistyakov
Andrei V. Chistyakov
ASAlon Sinai
Alon Sinai
AZAbraham Zangen
Abraham Zangen
MZMenashe Zaaroor
Menashe Zaaroor

1 May 2021 in Journal of Psychiatric Research
Verified
Journal Article
Open access
YRYiftach Roth
Yiftach Roth
Aron TendlerAron Tendler
Aron Tendler
MAMehmet Kemal Arikan
Mehmet Kemal Arikan
RVRyan Vidrine
Ryan Vidrine
DKDavid Kent
David Kent
AZAbraham Zangen
Abraham Zangen
Deep transcranial magnetic stimulation (dTMS) with the H7-coil was FDA cleared for obsessive-compulsive disorder (OCD) in August 2018 based on multicenter sham-controlled studies. Here we look at the efficacy of dTMS for OCD in real world practices. All dTMS clinics were asked to supply their data on treatment details and outcome measures. The primary outcome measure was response, defined by at least a 30% reduction in the Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline to endpoint. Secondary outcome measures included first response, defined as the first time the YBOCS score has met response criteria, and at least one-month sustained response. Analyses included response rate at the endpoint (after 29 dTMS sessions), number of sessions and days required to reach first response and sustained response. Twenty-two clinical sites with H7-coils provided data on details of treatment and outcome (YBOCS) measures from a total of 219 patients. One-hundred-sixty-seven patients who had at least one post-baseline YBOCS measure were included in the main analyses. Overall first and sustained response rates were 72.6% and 52.4%, respectively. The response rate was 57.9% in patients who had YBOCS scores after 29 dTMS sessions. First response was achieved in average after 18.5 sessions (SD = 9.4) or 31.6 days (SD = 25.2). Onset of sustained one-month response was achieved in average after 20 sessions (SD = 9.8) or 32.1 days (SD = 20.5). Average YBOCS scores demonstrated continuous reduction with increasing numbers of dTMS sessions. In real-world clinical practice, the majority of OCD patients benefitted from dTMS, and the onset of improvement usually occurs within 20 sessions. Extending the treatment course beyond 29 sessions results in continued reduction of OCD symptoms, raising the prospect of value for extended treatment protocols in non-responders.

15 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGaby S. Pell
Gaby S. Pell
THTal Harmelech
Tal Harmelech
SZSam Zibman
Sam Zibman
YRYiftach Roth
Yiftach Roth
Aron TendlerAron Tendler
Aron Tendler
AZAbraham Zangen
Abraham Zangen
(1) Background: While the therapeutic efficacy of Transcranial Magnetic Stimulation (TMS) for major depressive disorder (MDD) is well established, less is known about the technique’s efficacy for treating comorbid anxiety. (2) Methods: Data were retrospectively analyzed from randomized controlled trials (RCTs) that used Deep TMS with the H1 Coil for MDD treatment. The primary endpoint was the difference relative to sham treatment following 4 weeks of stimulation. The effect size was compared to literature values for superficial TMS and medication treatments. (3) Results: In the pivotal RCT, active Deep TMS compared with sham treatment showed significantly larger improvements in anxiety score (effect size = 0.34, p = 0.03 (FDR)) which were sustained until 16 weeks (effect size = 0.35, p = 0.04). The pooled effect size between all the RCTs was 0.55, which compares favorably to alternative treatments. A direct comparison to Figure-8 Coil treatment indicated that treatment with the H1 Coil was significantly more effective (p = 0.042). In contrast to previously reported studies using superficial TMS and medication for which anxiety has been shown to be a negative predictor of effectiveness, higher baseline anxiety was found to be predictive of successful outcome for the H1-Coil treatment. (4) Conclusions: Deep TMS is effective in treating comorbid anxiety in MDD and, unlike alternative treatments, the outcome does not appear to be adversely affected by high baseline anxiety levels.

1 January 2011 in Annals of General Psychiatry
Verified
Journal Article
Open access
PDF file
OROded Rosenberg
Oded Rosenberg
YRYiftach Roth
Yiftach Roth
MKMoshe Kotler
Moshe Kotler
AZAbraham Zangen
Abraham Zangen
PDPinhas Dannon
Pinhas Dannon
Schizophrenia is a chronic and disabling disease that presents with delusions and hallucinations. Auditory hallucinations are usually expressed as voices speaking to or about the patient. Previous studies have examined the effect of repetitive transcranial magnetic stimulation (TMS) over the temporoparietal cortex on auditory hallucinations in schizophrenic patients. Our aim was to explore the potential effect of deep TMS, using the H coil over the same brain region on auditory hallucinations.

8 October 2018 in IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology
Verified
Journal Article
Closed access
Serena FiocchiSerena Fiocchi
Serena Fiocchi
Emma ChiaramelloEmma Chiaramello
Emma Chiaramello
Livio LuziLivio Luzi
Livio Luzi
AFAnna Ferrulli
Anna Ferrulli
Marta BonatoMarta Bonato
Marta Bonato
Marta ParazziniMarta Parazzini
Marta Parazzini
Deep Transcranial Magnetic Stimulation (dTMS) is a neurostimulation technique for deep brain structures that has recently been successfully applied in the clinic for treatment of addiction. In contrast to conventional magnetic stimulation, which uses planar coils (figure-of-8) to target specific superficial regions of the brain, dTMS requires the design of complex three-dimensional coils in order to induce deeply penetrating fields. Recent clinical studies have focused on the use of H4 coils, which utilizes a left-right symmetric structure for bilateral stimulation of the prefrontal cortex, and demonstrated efficacy for therapy such as smoking cessation. The mechanism of activity, however, remains poorly understood, in part because the affected regions of the brain are not known in detail. To this purpose, computational techniques applied to highly detailed inhomogeneous tissue phantoms, provide a powerful tool for testing coil efficacy. In this work we quantified both electric field E distribution and its penetration depth in the prefrontal cortex, induced by a specific Hesed-coil, H4, designed for the addiction treatment and by the traditional figure-of-8 coil for comparison. Results show that H4 coil preferentially targets insula and cingulate cortex. Moreover, it can induce in the deepest tissues E amplitude ranging between the 20-40% of the cortical peak and it can penetrate the cortex up to 4 cm with a E>50% of the cortical peak, thus noticeably increasing the penetration depth of the traditional TMS systems.

24 March 2023 in Psychiatry Research
Verified
Journal Article
Open access
Aron TendlerAron Tendler
Aron Tendler
SGStephan Goerigk
Stephan Goerigk
SZSamuel Zibman
Samuel Zibman
SOSalomé Ouaknine
Salomé Ouaknine
THTal Harmelech
Tal Harmelech
YRYiftach Roth
Yiftach Roth
Phase IV study evaluated Deep TMS for major depression in community settings. Data were aggregated from 1753 patients at 21 sites, who received Deep TMS (high frequency or iTBS) using the H1 coil. Outcome measures varied across subjects and included clinician-based scales (HDRS-21) and self-assessment questionnaires (PHQ-9, BDI-II). 1351 patients were included in the analysis, 202 received iTBS. For participants with data from at least 1 scale, 30 sessions of Deep TMS led to 81.6% response and 65.3% remission rate. 20 sessions led to 73.6% response and 58.1% remission rate. iTBS led to 72.4% response and 69.2% remission. Remission rates were highest when assessed with HDRS (72%). In 84% of responders and 80% of remitters, response and remission was sustained in the subsequent assessment. Median number of sessions (days) for onset of sustained response was 16 (21 days) and for sustained remission 17 (23 days). Higher stimulation intensity was associated with superior clinical outcomes. This study shows that beyond its proven efficacy in RCTs, Deep TMS with the H1 coil is effective for treating depression under naturalistic conditions, and the onset of improvement is usually within 20 sessions. However, initial non-responders and non-remitters benefit from extended treatment.